Reduced ABCG2 and increased SLC22A1 mRNA expression are associated with imatinib response in chronic myeloid leukemia. (Q46788822)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24469953%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

title

Reduced ABCG2 and increased SLC22A1 mRNA expression are associated with imatinib response in chronic myeloid leukemia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24469953%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

main subject

chronic myeloid leukemia

0 references

1 reference

1 reference

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24469953%20AND%20SRC:MED&resulttype=core&format=json

Elvira M Guerra-Shinohara

6 March 2020

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24469953%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

author name string

Luciene Terezina de Lima

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24469953%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Douglas Vivona

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24469953%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Carolina Tosin Bueno

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24469953%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Rosario D C Hirata

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24469953%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Mario H Hirata

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24469953%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Fabíola Attié de Castro

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24469953%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Maria de Lourdes F Chauffaille

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24469953%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Maria A Zanichelli

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24469953%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Carlos S Chiattone

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24469953%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Vania T M Hungria

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24469953%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

publication date

29 January 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24469953%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24469953%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

volume

31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24469953%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24469953%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

page(s)

851

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24469953%20AND%20SRC:MED&resulttype=core&format=json

The impact of gene profiling in chronic myeloid leukaemia

6 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0851-5

Drug transporters and imatinib treatment: implications for clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0851-5

Mechanisms of resistance to BCR-ABL kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0851-5

Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0851-5

Initial treatment for patients with CML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0851-5

Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0851-5

Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0851-5

Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0851-5

Interaction of imatinib with human organic ion carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0851-5

hOCT 1 and resistance to imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0851-5

Constitutive overexpression of P-glycoprotein, rather than breast cancer resistance protein or organic cation transporter 1, contributes to acquisition of imatinib-resistance in K562 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0851-5

Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0851-5

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0851-5

Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0851-5

Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0851-5

Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0851-5

BCR-ABL in chronic myelogenous leukemia--how does it work?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0851-5

Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0851-5

Role of P-glycoprotein in evolution of populations of chronic myeloid leukemia cells treated with imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0851-5

Effect of interferon-α2b on the expression of various drug-metabolizing enzymes and transporters in co-cultures of freshly prepared human primary hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0851-5

Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0851-5

Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0851-5

Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0851-5

OCT-1 as a determinant of response to antileukemic treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0851-5

Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0851-5

Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0851-5

Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0851-5

Dasatinib targets chronic myeloid leukemia-CD34+ progenitors as effectively as it targets mature cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0851-5

Single nucleotide polymorphisms modify the transporter activity of ABCG2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0851-5

Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0851-5

Major SNP (Q141K) variant of human ABC transporter ABCG2 undergoes lysosomal and proteasomal degradations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0851-5

Association of breast cancer resistance protein/ABCG2 phenotypes and novel promoter and intron 1 single nucleotide polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0851-5

Correlation between imatinib pharmacokinetics and clinical response in Japanese patients with chronic-phase chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0851-5

A multicenter clinical study evaluating the confirmed complete molecular response rate in imatinib-treated patients with chronic phase chronic myeloid leukemia by using the international scale of real-time quantitative polymerase chain reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0851-5

Complex interaction of BCRP/ABCG2 and imatinib in BCR-ABL-expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0851-5

Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0851-5

OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0851-5

Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics

21 January 2018

1 reference

12 December 2020

The molecular biology of chronic myeloid leukemia.

1 reference

12 December 2020

Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes

1 reference

12 December 2020

Development of imatinib and dasatinib resistance: dynamics of expression of drug transportersABCB1, ABCC1, ABCG2, MVP, and SLC22A1

1 reference

12 December 2020

C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance.

1 reference

12 December 2020

Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia

1 reference

12 December 2020

Organic cation transporters

1 reference

12 December 2020

Instability of mRNA expression signatures of drug transporters in chronic myeloid leukemia patients resistant to imatinib.

1 reference

12 December 2020